Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.67 |
| ▸ | PI4KA | P42356 | 4/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.50 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22381523 | 0.89 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22571151 | 0.84 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL16707341 | 0.78 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18520815 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18510346 | 0.75 | ADORA3 (0.39) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL22326770 | 0.75 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL4054756 | 0.74 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22571152 | 0.73 | PI4KA (0.50) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18526490 | 0.73 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22326710 | 0.73 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2020117623-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117625-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117624-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885ADORA2B 827/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | ADORA2A 317/4885ADORA1 407/4885ADORA2B 621/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA2A 368/4885ADORA1 344/4885ADORA2B 686/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 228/4885ADORA1 314/4885ADORA2B 1162/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA2A 73/4885ADORA1 32/4885ADORA2B 144/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | ADORA2A 216/4885ADORA1 884/4885ADORA2B 859/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA2A 368/4885ADORA1 344/4885ADORA2B 686/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 900/4885ADORA1 1640/4885ADORA2B 2261/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA2A 69/4885ADORA1 33/4885ADORA2B 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.